搜索


PM1092
Category
Back To List
Product description
Parameters
Our next-generation Treg depletion assets focus on targeting CCR8, which is highly upregulated on tumour-infiltrating Tregs. To improve specificity in depleting Tregs in the TME, a second arm has been targeted (CTLA-4) to minimize the depletion of CCR8- or CTLA-4-expressing effector cells such as cytotoxic CD4+ and CD8+ T cells. PM1092 has a 1+1 heterodimeric structure, where the affinities of both the CCR8- and CTLA-4-targeting arms have been optimized for binding and activity towards CCR8/CTLA-4 double-positive cells. In preclinical studies, the CCR8 x CTLA-4 bispecific has better safety than other benchmark anti-CTLA-4 mAbs, and performs better than mAbs targeting CCR8 or CTLA-4 alone for tumor inhibition.
Scan the QR code to read on your phone
Previous
PM1080
Next
Multiple ADC